Balsalazide: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
Line 1: Line 1:
{{drugbox
{{DrugProjectFormSinglePage
| IUPAC_name = 5-[4-(2-carboxyethylcarbamoyl)phenyl]diazenyl-2-hydroxy-benzoic acid
|authorTag=
| image = Balsalazide.png
 
| CAS_number = 80573-04-2
{{VP}}
| ATC_prefix = A07
 
| ATC_suffix = EC04
<!--Overview-->
| ATC_supplemental =  
 
| PubChem = 5362070
|genericName=
| DrugBank = APRD00141
 
| C=17 | H=15 | N=3 | O=6
 
| molecular_weight = 357.318 g/mol
 
| bioavailability = <1%
|aOrAn=
| protein_bound = ≥99%
 
| metabolism =  
a
| elimination_half-life = 12hr
 
| pregnancy_US = B
|drugClass=
| pregnancy_category =  
 
| legal_status = POM [UK]
locally acting aminosalicylate
| routes_of_administration =  
 
}}
|indication=
 
mildly to moderately active [[ulcerative colitis]] in adults
 
|hasBlackBoxWarning=
 
|adverseReactions=
 
[[headache]], [[abdominal pain]], [[diarrhea]], [[nausea]], [[vomiting]], [[respiratory infection]], and [[arthralgia]]
 
<!--Black Box Warning-->
 
|blackBoxWarningTitle=
Title
 
|blackBoxWarningBody=
<i><span style="color:#FF0000;">ConditionName: </span></i>
 
* Content
 
<!--Adult Indications and Dosage-->
 
<!--FDA-Labeled Indications and Dosage (Adult)-->
 
|fdaLIADAdult=
 
=====Ulcerative Colitis=====
 
* For treatment of active ulcerative colitis in adult patients, the usual dose is three 750 mg balsalazide disodium capsules to be taken 3 times a day (6.75 g per day) for up to 8 weeks. Some patients in the adult clinical trials required treatment for up to 12 weeks.
 
*Balsalazide disodium capsules may also be administered by carefully opening the capsule and sprinkling the capsule contents on applesauce. The entire drug/applesauce mixture should be swallowed immediately; the contents may be chewed, if necessary, since contents of balsalazide disodium capsules are NOT coated beads/granules. Patients should be instructed not to store any drug/applesauce mixture for future use.
 
*If the capsules are opened for sprinkling, color variation of the powder inside the capsules ranges from orange to yellow and is expected due to color variation of the active pharmaceutical ingredient.
 
*Teeth and/or tongue staining may occur in some patients who use balsalazide disodium capsules in sprinkle form with food.
 
<!--Off-Label Use and Dosage (Adult)-->
 
<!--Guideline-Supported Use (Adult)-->
 
|offLabelAdultGuideSupport=
 
=====Condition1=====
 
* Developed by:
 
* Class of Recommendation:
 
* Strength of Evidence:
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
 
<!--Non–Guideline-Supported Use (Adult)-->
 
|offLabelAdultNoGuideSupport=
 
=====Condition1=====
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
 
<!--Pediatric Indications and Dosage-->
 
<!--FDA-Labeled Indications and Dosage (Pediatric)-->
 
|fdaLIADPed=
 
=====Condition1=====
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.
 
<!--Off-Label Use and Dosage (Pediatric)-->
 
<!--Guideline-Supported Use (Pediatric)-->
 
|offLabelPedGuideSupport=
 
=====Condition1=====
 
* Developed by:
 
* Class of Recommendation:
 
* Strength of Evidence:
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 
<!--Non–Guideline-Supported Use (Pediatric)-->
 
|offLabelPedNoGuideSupport=
 
=====Condition1=====
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 
<!--Contraindications-->
 
|contraindications=
 
* Patients with [[hypersensitivity]] to salicylates or to any of the components of balsalazide disodium capsules or balsalazide metabolites. [[Hypersensitivity]] reactions may include, but are not limited to the following: [[anaphylaxis]], [[bronchospasm]], and skin reaction.
 
<!--Warnings-->
 
|warnings=
 
====Precautions====
 
*  Exacerbations of Ulcerative Colitis
:*In the adult clinical trials, 3 out of 259 patients reported exacerbation of the symptoms of [[ulcerative colitis]].
:*Observe patients closely for worsening of these symptoms while on treatment.
 
*Pyloric Stenosis
:*Patients with [[pyloric stenosis]] may have prolonged gastric retention of balsalazide disodium capsules.
 
*Renal
:*Renal toxicity has been observed in animals and patients given other mesalamine products. Therefore, caution should be exercised when administering balsalazide capsules to patients with known [[renal dysfunction]] or a history of [[renal disease]].
 
<!--Adverse Reactions-->
 
<!--Clinical Trials Experience-->
 
|clinicalTrials=
 
=====Adult Ulcerative Colitis=====
 
*During clinical development, 259 adult patients with active ulcerative colitis were exposed to 6.75 g/day balsalazide in 4 controlled trials.
 
*In the 4 controlled clinical trials patients receiving a balsalazide dose of 6.75 g/day most frequently reported the following adverse reactions: [[headache]] (8%), [[abdominal pain]] (6%), [[diarrhea]] (5%), [[nausea]] (5%), [[vomiting]] (4%), [[respiratory infection]] (4%), and [[arthralgia]] (4%). Withdrawal from therapy due to adverse reactions was comparable among patients on balsalazide and placebo.
 
*Adverse reactions reported by 1% or more of patients who participated in the four well controlled, Phase 3 trials are presented by treatment group (Table 1).
 
*The number of placebo patients (35), however, is too small for valid comparisons. Some adverse reactions, such as [[abdominal pain]], [[fatigue]], and [[nausea]] were reported more frequently in women than in men. [[Abdominal pain]], [[rectal bleeding]], and [[anemia]] can be part of the clinical presentation of [[ulcerative colitis]].
 
T1
 
<!--Postmarketing Experience-->
 
|postmarketing=
 
*The following adverse reactions have been identified during post-approval use of balsalazide in clinical practice:
:*[[myocarditis]], [[pericarditis]], [[vasculitis]], [[pruritus]], [[pleural effusion]], [[pneumonia]] (with and without [[eosinophilia]]), [[alveolitis]], [[renal failure]], [[interstitial nephritis]], [[pancreatitis]], and [[alopecia]].
 
*Because these reactions are reported voluntarily from a population of unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These adverse reactions have been chosen for inclusion due to a combination of seriousness, frequency of reporting, or potential causal connection to balsalazide.
 
*Hepatic
:*Postmarketing adverse reactions of hepatotoxicity have been reported for products which contain (or are metabolized to) [[mesalamine]], including elevated liver function tests (SGOT/AST, [[SGPT]]/[[ALT]], [[GGT]], [[LDH]], [[alkaline phosphatase]], [[bilirubin]]), [[jaundice]], [[cholestatic jaundice]], [[cirrhosis]], hepatocellular damage including [[liver necrosis]] and [[liver failure]]. Some of these cases were fatal; however, no fatalities associated with these adverse reactions were reported in balsalazide clinical trials. One case of Kawasaki-like syndrome which included hepatic function changes was also reported, however, this adverse reaction was not reported in balsalazide clinical trials.  
 
<!--Drug Interactions-->
 
|drugInteractions=
 
* In an in vitro study using human liver microsomes, balsalazide and its metabolites [5-aminosalicylic acid (5-ASA), N-acetyl-5-aminosalicylic acid (N-Ac-5-ASA), 4-aminobenzoyl-β-alanine (4-ABA) and N-acetyl-4-aminobenzoyl-β–alanine (N-Ac-4-ABA)] were not shown to inhibit the major CYP enzymes evaluated (CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4/5). Therefore, balsalazide and its metabolites are not expected to inhibit the metabolism of other drugs which are substrates of CYP1A2, CYP2C9, CYP2C19, CYP2D6, or CYP3A4/5.
 
<!--Use in Specific Populations-->
 
|useInPregnancyFDA=
* '''Pregnancy Category B'''
 
*Reproduction studies were performed in rats and rabbits at oral doses up to 2 g/kg/day, 2.4 and 4.7 times the recommended human dose based on body surface area for the rat and rabbit, respectively, and revealed no evidence of impaired fertility or harm to the fetus due to balsalazide disodium. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
 
|useInPregnancyAUS=
* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
 
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant.
 
|useInLaborDelivery=
There is no FDA guidance on use of {{PAGENAME}} during labor and delivery.
 
|useInNursing=
 
*It is not known whether balsalazide disodium is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when balsalazide is administered to a nursing woman.
 
|useInPed=
 
*Pediatric use information is protected by marketing exclusivity.
 
|useInGeri=
There is no FDA guidance on the use of {{PAGENAME}} with respect to geriatric patients.
 
|useInGender=
There is no FDA guidance on the use of {{PAGENAME}} with respect to specific gender populations.
 
|useInRace=
There is no FDA guidance on the use of {{PAGENAME}} with respect to specific racial populations.
 
|useInRenalImpair=
There is no FDA guidance on the use of {{PAGENAME}} in patients with renal impairment.
 
|useInHepaticImpair=
There is no FDA guidance on the use of {{PAGENAME}} in patients with hepatic impairment.
 
|useInReproPotential=
There is no FDA guidance on the use of {{PAGENAME}} in women of reproductive potentials and males.
 
|useInImmunocomp=
There is no FDA guidance one the use of {{PAGENAME}} in patients who are immunocompromised.
 
<!--Administration and Monitoring-->
 
|administration=
 
* Oral
 
|monitoring=
 
There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.
 
<!--IV Compatibility-->
 
|IVCompat=
 
There is limited information regarding <i>IV Compatibility</i> of {{PAGENAME}} in the drug label.
 
<!--Overdosage-->
 
|overdose=
 
===Acute Overdose===
 
*No case of overdose has occurred with balsalazide. A 3-year-old boy is reported to have ingested 2 g of another mesalamine product. He was treated with ipecac and activated charcoal with no adverse reactions.
 
*If an overdose occurs with balsalazide, treatment should be supportive, with particular attention to correction of electrolyte abnormalities.
 
===Chronic Overdose===
 
There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label.
 
<!--Pharmacology-->
 
<!--Drug box 2-->
 
|drugBox=
 
 
 
<!--Mechanism of Action-->
 
|mechAction=
 
* Balsalazide disodium is delivered intact to the colon where it is cleaved by bacterial azoreduction to release equimolar quantities of mesalamine, which is the therapeutically active portion of the molecule, and the 4-aminobenzoyl-β-alanine carrier moiety. The carrier moiety released when balsalazide disodium is cleaved is only minimally absorbed and is largely inert.
 
*The mechanism of action of 5-ASA is unknown, but appears to be local to the colonic mucosa rather than systemic. Mucosal production of arachidonic acid metabolites, both through the cyclooxygenase pathways, i.e., prostanoids, and through the lipoxygenase pathways, i.e., leukotrienes and hydroxyeicosatetraenoic acids, is increased in patients with chronic inflammatory bowel disease, and it is possible that 5-ASA diminishes inflammation by blocking production of arachidonic acid metabolites in the colon.
 
<!--Structure-->
 
|structure=
 
*
 
: [[File:{{PAGENAME}}01.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
 
<!--Pharmacodynamics-->
 
|PD=
 
There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label.
 
<!--Pharmacokinetics-->
 
|PK=
 
There is limited information regarding <i>Pharmacokinetics</i> of {{PAGENAME}} in the drug label.
 
<!--Nonclinical Toxicology-->
 
|nonClinToxic=
 
There is limited information regarding <i>Nonclinical Toxicology</i> of {{PAGENAME}} in the drug label.
 
<!--Clinical Studies-->
 
|clinicalStudies=
 
There is limited information regarding <i>Clinical Studies</i> of {{PAGENAME}} in the drug label.
 
<!--How Supplied-->
 
|howSupplied=
 
*
 
<!--Patient Counseling Information-->
 
|fdaPatientInfo=
 
There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.
 
<!--Precautions with Alcohol-->
 
|alcohol=
 
* Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
 
<!--Brand Names-->
 
|brandNames=
 
* ®<ref>{{Cite web | title =  | url =  }}</ref>
 
<!--Look-Alike Drug Names-->
 
|lookAlike=


==Overview==
* A® — B®<ref name="www.ismp.org">{{Cite web  | last = | first = | title = http://www.ismp.org | url = http://www.ismp.org | publisher =  | date =  }}</ref>
'''Balsalazide''' is an anti-inflammatory drug used in the treatment of [[Inflammatory Bowel Disease]]. It is sold under the name "Colazal" in the US and "Colazide" in the UK.


The chemical name is (E)-5-[[-4-[[(2-carboxyethyl) amino]]carbonyl] phenyl]azo] -2-hydroxybenzoic acid. It is usually administered as the disodium salt.
<!--Drug Shortage Status-->


Balsalazide releases [[mesalazine]], also known as 5-aminosalicylic acid, or 5-ASA, in the large intestine. Its advantage over that drug in the treatment of [[Ulcerative colitis]] is believed to be the delivery of the active agent past the small intestine to the large intestine, the active site of ulcerative colitis.
|drugShortage=
}}


==Pill Images==
<!--Pill Image-->
{{TempDrugImages}}
{{PillImage|fileName=Balsalazide_Disodium_NDC_00540079.jpg|drugName=Balsalazide Disodium|NDC=00540079|drugAuthor=Roxane Laboratories, Inc|ingredients=BALSALAZIDE DISODIUM[BALSALAZIDE]|pillImprint=54;795|dosageValue=750|dosageUnit=mg|pillColor=Orange|pillShape=Capsule|pillSize=1|pillScore=1}}
{{PillImage|fileName=Balsalazide_Disodium_NDC_03786750.jpg|drugName=Balsalazide Disodium|NDC=03786750|drugAuthor=Mylan Pharmaceuticals Inc.|ingredients=BALSALAZIDE DISODIUM[BALSALAZIDE]|pillImprint=MYLAN;6750|dosageValue=750|dosageUnit=mg|pillColor=Orange|pillShape=Capsule|pillSize=23|pillScore=1}}
{{PillImage|fileName=COLAZAL_NDC_656490101.jpg|drugName=COLAZAL|NDC=656490101|drugAuthor=Salix Pharmaceuticals, Inc.|ingredients=BALSALAZIDE DISODIUM[BALSALAZIDE]|pillImprint=CZ|dosageValue=10|dosageUnit=mg|pillColor=White|pillShape=Capsule|pillSize=23|pillScore=1}}


{{PillImage
|fileName=No image.jpg|This image is provided by the National Library of Medicine.
|drugName=
|NDC=
|drugAuthor=
|ingredients=
|pillImprint=
|dosageValue=
|dosageUnit=
|pillColor=
|pillShape=
|pillSize=
|pillScore=
}}


==External links==
<!--Label Display Image-->


*[http://www.fda.gov/cder/consumerinfo/druginfo/colazal.HTM FDA Colazal Info]
{{LabelImage
*[http://www.fda.gov/cder/foi/label/2000/20610lbl.pdf Colazal Label (PDF)]
|fileName={{PAGENAME}}11.png|This image is provided by the National Library of Medicine.
}}


{{Antidiarrheals, intestinal anti-inflammatory/anti-infective agents}}
{{LabelImage
|fileName={{PAGENAME}}11.png|This image is provided by the National Library of Medicine.
}}


<!--Category-->


[[Category:Drugs]]
[[Category:Drug]]
{{jb1}}
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}

Revision as of 15:23, 16 February 2015

Balsalazide
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vignesh Ponnusamy, M.B.B.S. [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Balsalazide is a locally acting aminosalicylate that is FDA approved for the {{{indicationType}}} of mildly to moderately active ulcerative colitis in adults. Common adverse reactions include headache, abdominal pain, diarrhea, nausea, vomiting, respiratory infection, and arthralgia.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Ulcerative Colitis
  • For treatment of active ulcerative colitis in adult patients, the usual dose is three 750 mg balsalazide disodium capsules to be taken 3 times a day (6.75 g per day) for up to 8 weeks. Some patients in the adult clinical trials required treatment for up to 12 weeks.
  • Balsalazide disodium capsules may also be administered by carefully opening the capsule and sprinkling the capsule contents on applesauce. The entire drug/applesauce mixture should be swallowed immediately; the contents may be chewed, if necessary, since contents of balsalazide disodium capsules are NOT coated beads/granules. Patients should be instructed not to store any drug/applesauce mixture for future use.
  • If the capsules are opened for sprinkling, color variation of the powder inside the capsules ranges from orange to yellow and is expected due to color variation of the active pharmaceutical ingredient.
  • Teeth and/or tongue staining may occur in some patients who use balsalazide disodium capsules in sprinkle form with food.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

Condition1
  • Developed by:
  • Class of Recommendation:
  • Strength of Evidence:
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Guideline-Supported Use of Balsalazide in adult patients.

Non–Guideline-Supported Use

Condition1
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of Balsalazide in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

Condition1
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding FDA-Labeled Use of Balsalazide in pediatric patients.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

Condition1
  • Developed by:
  • Class of Recommendation:
  • Strength of Evidence:
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Guideline-Supported Use of Balsalazide in pediatric patients.

Non–Guideline-Supported Use

Condition1
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of Balsalazide in pediatric patients.

Contraindications

Warnings

Precautions

  • Exacerbations of Ulcerative Colitis
  • In the adult clinical trials, 3 out of 259 patients reported exacerbation of the symptoms of ulcerative colitis.
  • Observe patients closely for worsening of these symptoms while on treatment.
  • Pyloric Stenosis
  • Patients with pyloric stenosis may have prolonged gastric retention of balsalazide disodium capsules.
  • Renal
  • Renal toxicity has been observed in animals and patients given other mesalamine products. Therefore, caution should be exercised when administering balsalazide capsules to patients with known renal dysfunction or a history of renal disease.

Adverse Reactions

Clinical Trials Experience

Adult Ulcerative Colitis
  • During clinical development, 259 adult patients with active ulcerative colitis were exposed to 6.75 g/day balsalazide in 4 controlled trials.
  • In the 4 controlled clinical trials patients receiving a balsalazide dose of 6.75 g/day most frequently reported the following adverse reactions: headache (8%), abdominal pain (6%), diarrhea (5%), nausea (5%), vomiting (4%), respiratory infection (4%), and arthralgia (4%). Withdrawal from therapy due to adverse reactions was comparable among patients on balsalazide and placebo.
  • Adverse reactions reported by 1% or more of patients who participated in the four well controlled, Phase 3 trials are presented by treatment group (Table 1).

T1

Postmarketing Experience

  • The following adverse reactions have been identified during post-approval use of balsalazide in clinical practice:
  • Because these reactions are reported voluntarily from a population of unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These adverse reactions have been chosen for inclusion due to a combination of seriousness, frequency of reporting, or potential causal connection to balsalazide.
  • Hepatic
  • Postmarketing adverse reactions of hepatotoxicity have been reported for products which contain (or are metabolized to) mesalamine, including elevated liver function tests (SGOT/AST, SGPT/ALT, GGT, LDH, alkaline phosphatase, bilirubin), jaundice, cholestatic jaundice, cirrhosis, hepatocellular damage including liver necrosis and liver failure. Some of these cases were fatal; however, no fatalities associated with these adverse reactions were reported in balsalazide clinical trials. One case of Kawasaki-like syndrome which included hepatic function changes was also reported, however, this adverse reaction was not reported in balsalazide clinical trials.

Drug Interactions

  • In an in vitro study using human liver microsomes, balsalazide and its metabolites [5-aminosalicylic acid (5-ASA), N-acetyl-5-aminosalicylic acid (N-Ac-5-ASA), 4-aminobenzoyl-β-alanine (4-ABA) and N-acetyl-4-aminobenzoyl-β–alanine (N-Ac-4-ABA)] were not shown to inhibit the major CYP enzymes evaluated (CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4/5). Therefore, balsalazide and its metabolites are not expected to inhibit the metabolism of other drugs which are substrates of CYP1A2, CYP2C9, CYP2C19, CYP2D6, or CYP3A4/5.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA):

  • Pregnancy Category B
  • Reproduction studies were performed in rats and rabbits at oral doses up to 2 g/kg/day, 2.4 and 4.7 times the recommended human dose based on body surface area for the rat and rabbit, respectively, and revealed no evidence of impaired fertility or harm to the fetus due to balsalazide disodium. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.


Pregnancy Category (AUS):

  • Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Balsalazide in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Balsalazide during labor and delivery.

Nursing Mothers

  • It is not known whether balsalazide disodium is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when balsalazide is administered to a nursing woman.

Pediatric Use

  • Pediatric use information is protected by marketing exclusivity.

Geriatic Use

There is no FDA guidance on the use of Balsalazide with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Balsalazide with respect to specific gender populations.

Race

There is no FDA guidance on the use of Balsalazide with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Balsalazide in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Balsalazide in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Balsalazide in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Balsalazide in patients who are immunocompromised.

Administration and Monitoring

Administration

  • Oral

Monitoring

There is limited information regarding Monitoring of Balsalazide in the drug label.

IV Compatibility

There is limited information regarding IV Compatibility of Balsalazide in the drug label.

Overdosage

Acute Overdose

  • No case of overdose has occurred with balsalazide. A 3-year-old boy is reported to have ingested 2 g of another mesalamine product. He was treated with ipecac and activated charcoal with no adverse reactions.
  • If an overdose occurs with balsalazide, treatment should be supportive, with particular attention to correction of electrolyte abnormalities.

Chronic Overdose

There is limited information regarding Chronic Overdose of Balsalazide in the drug label.

Pharmacology

There is limited information regarding Balsalazide Pharmacology in the drug label.

Mechanism of Action

  • Balsalazide disodium is delivered intact to the colon where it is cleaved by bacterial azoreduction to release equimolar quantities of mesalamine, which is the therapeutically active portion of the molecule, and the 4-aminobenzoyl-β-alanine carrier moiety. The carrier moiety released when balsalazide disodium is cleaved is only minimally absorbed and is largely inert.
  • The mechanism of action of 5-ASA is unknown, but appears to be local to the colonic mucosa rather than systemic. Mucosal production of arachidonic acid metabolites, both through the cyclooxygenase pathways, i.e., prostanoids, and through the lipoxygenase pathways, i.e., leukotrienes and hydroxyeicosatetraenoic acids, is increased in patients with chronic inflammatory bowel disease, and it is possible that 5-ASA diminishes inflammation by blocking production of arachidonic acid metabolites in the colon.

Structure

This image is provided by the National Library of Medicine.

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Balsalazide in the drug label.

Pharmacokinetics

There is limited information regarding Pharmacokinetics of Balsalazide in the drug label.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Balsalazide in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Balsalazide in the drug label.

How Supplied

Storage

There is limited information regarding Balsalazide Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Balsalazide |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Balsalazide |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Patient Counseling Information of Balsalazide in the drug label.

Precautions with Alcohol

  • Alcohol-Balsalazide interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

Look-Alike Drug Names

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

  1. ↑ Empty citation (help)
  2. ↑ "http://www.ismp.org". External link in |title= (help)


{{#subobject: 

 |Page Name=Balsalazide
 |Pill Name=No image.jpg
 |Drug Name=
 |Pill Ingred=|+sep=;
 |Pill Imprint=
 |Pill Dosage=
 |Pill Color=|+sep=;
 |Pill Shape=
 |Pill Size (mm)=
 |Pill Scoring=
 |Pill Image=
 |Drug Author=
 |NDC=

}}


{{#subobject: 

 |Label Page=Balsalazide
 |Label Name=Balsalazide11.png

}}


{{#subobject: 

 |Label Page=Balsalazide
 |Label Name=Balsalazide11.png

}}

Retrieved from "https://www.wikidoc.org/index.php?title=Balsalazide&oldid=1068733"